Clopidogrel May Be Superior to Aspirin as Maintenance Antiplatelet Monotherapy in Patients With Non-Cardioembolic Ischemic Stroke

Figure 1.Kaplan-Meier curves for outcome events according to antiplatelet agent.Cumulative incidences of (A) net adverse clinical and cerebral events (NACCE), (B) major adverse cardiovascular events (MACE), (C) acute coronary syndrome, (D) any stroke, (E) recurrent acute ischemic stroke, (F) intracranial bleeding, (G) major bleeding, and (H) death. Cumulative event (%)Cumulative event (%)Cumulative event (%)Cumulative event (%) Cumulative event (%)Cumulative event (%) Cumulative event (%) Time to event (days) Time to event (days) Time to event (days) Time to event (days) Time to event (days) Time to event (days) Time to event (days) No. at risk Aspirin Clopidogrel No. at risk Aspirin Clopidogrel No. at risk Aspirin Clopidogrel No. at risk Aspirin Clopidogrel No. at risk Aspirin Clopidogrel No. at risk Aspirin Clopidogrel No.